Skip to main content
DRUG COSTS

Out of control—or delivering value?

Efficacy within reach

Is affordability a pipe dream?

article

Complexities in forecasting eligible cases and associated costs of cell and gene therapy

Read the articleNavigation Arrow
article

An end to manufacturer rebates as we know them today?

Read the articleNavigation Arrow
Resource Card Placeholder
WHITE PAPER

Payer strategies for GLP-1 medications for weight loss

We examine various strategies related to GLP-1 medications such as Wegovy when used for weight loss to help payers understand the landscape, develop a coverage strategy, and minimize waste.
Resource Card Placeholder
Article

NADAC-plus: An emerging paradigm in pharmacy pricing

LWith increased consumer and regulatory scrutiny on drug prices, stakeholders in the pharmacy supply chain are exploring drug pricing alternatives.

Resource Card Placeholder
Article

Medicare Part D risk and claim cost changes with the Inflation Reduction Act

The Medicare Part D program is on the verge of massive change due to passage of the Inflation Reduction Act.

Products

Related Milliman products

Pharmaceutical claims analytics

MyRxConsultant

Learn moreNavigation Arrow
ACA compliance & affordability

Healthcare Reform Dashboard

Learn moreNavigation Arrow
Healthcare analytics

MedInsight

Learn moreNavigation Arrow
Services

Related Milliman services

We’re here to help